BiologicsMD, Inc.

BiologicsMD is an early stage, therapeutic research and development company focused on developing highly-targeted, human therapeutics and therapeutic-device combinations for the treatment of bone and hair-loss disorders.

The Company’s core technology relies on targeting physiologically active agents to Type I collagen, found in bone and skin, via fusion to a proprietary collagen-binding domain. BiologicsMD has developed a series of recombinant fusion proteins that specifically target the parathyroid hormone (PTH) receptor pathway with sustained activity at a low total dose (bioactive for a period of months from a single application). Importantly, for the lead indications of spinal fusion and fracture repair, targeting the PTH receptor pathway activates multiple components of bone formation and remodeling, providing a more complete repair response than other osteobiologic agents. BiologicsMD’s approach minimizes off-target effects (e.g. hypercalcemia and kidney stones) and increases the time of exposure at the targeted sites, thereby reducing both the frequency of dosing and the total amount of drug required.

BiologicsMD’s lead program, BMD-1231, is a therapeutic-device combination that has a proven and potent profile in bone osteogenesis, and is being developed to facilitate spinal fusions in degenerative disk disease and reduce the number of incomplete fusions (pseudarthrosis). Despite current surgical techniques and advanced surgical hardware, further clinical advances are needed to reduce the number of incomplete unions, provide faster fracture healing, and greatly reduce the need for secondary interventions and additional surgeries. The company is initially focusing on spinal fusion surgical procedures to aid in the complete fusion of the targeted vertebrae, which currently has only a 70-75% success rate with the first surgery.

Source: ICNW